Your browser doesn't support javascript.
loading
Empagliflozin: Primus Inter Pares Among Sodium-Glucose Cotransporter-2 Inhibitors?
Biondi-Zoccai, Giuseppe; Frati, Giacomo; Peruzzi, Mariangela; Booz, George W.
Afiliación
  • Biondi-Zoccai G; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
  • Frati G; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
  • Peruzzi M; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
  • Booz GW; IRCCS NEUROMED, Pozzilli, Italy.
J Cardiovasc Pharmacol ; 84(3): 271-275, 2024 Sep 01.
Article en En | MEDLINE | ID: mdl-39027982
ABSTRACT
ABSTRACT Sodium/glucose cotransporter-2 (SGLT2) inhibitors are a novel class of antidiabetic medications which have proved capable of providing breakthrough cardiovascular (CV) benefits in a variety of clinical scenarios, including patients with heart failure or obesity, irrespective of diabetic status. Several SGLT2 inhibitors are available, but the most prominent ones are canagliflozin, dapagliflozin, and empagliflozin. Several studies have focused on empagliflozin and its effects on the risk of heart failure incidence and recurrences. Most recently, empagliflozin has been recently tested in patients with recent myocardial infarction in the EMPAgliflozin on Hospitalization for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction randomized trial, with apparently ambiguous findings. The present viewpoint succinctly illustrates the main features of SGLT2 inhibitors as a pharmacologic class, their ever expanding role as a CV medication, and the comparative effectiveness of different individual SGLT2 inhibitors, explicitly commenting on the recent data on empagliflozin in patients with acute myocardial infarction. The reader will find in this article a poignant perspective on this novel avenue for CV prevention and treatment, which greatly expands the management armamentarium of CV practitioners. Indeed, we make the case that SGLT2 inhibitors have a clearly favorable class effect, with differences between individual agents mainly suitable for personalization of care and minimization of side effects.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Bencidrilo / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Glucósidos Límite: Animals / Humans Idioma: En Revista: J Cardiovasc Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Bencidrilo / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Glucósidos Límite: Animals / Humans Idioma: En Revista: J Cardiovasc Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos